Diabetes, Metabolic Syndrome and Obesity (Mar 2022)
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
Abstract
Hiroki Teragawa,1 Takeshi Morimoto,2 Yuichi Fujii,1 Tomohiro Ueda,1 Mio Sakuma,2 Michio Shimabukuro,3 Osamu Arasaki,4 Koichi Node,5 Takashi Nomiyama,6 Shinichiro Ueda7 1Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan; 2Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan; 3Deparment of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan; 4Department of Cardiology, Yuuai Medical Center, Tomigusuku, Okinawa, Japan; 5Department of Cardiovascular Medicine, Saga University, Saga, Japan; 6Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan; 7Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Okinawa, JapanCorrespondence: Hiroki Teragawa, Department of Cardiovascular Medicine, JR Hiroshima Hospital, 3-1-36 Futabanosato, Higashi-ku, Hiroshima, 732-0052, Japan, Tel +81-82-262-1171, Fax +81-82-262-1449, Email [email protected]: The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.Patients and methods: We measured the estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, and blood pressure (BP).Results: No significant differences were found in baseline eGFR and UACR between the two groups. The eGFR levels were significantly decreased in both groups; however, the UACR level was unchanged in the ANA group but elevated in the SITA group, although the difference did not reach significance between the two groups. The difference in eGFR was affected by the differences in HbA1c level and BP, and the difference in the UACR was affected by the differences in LDL-C level and BP, which were reduced only in the ANA group.Conclusion: These findings imply that the effects of DPP-4 inhibitors on renal function, especially on UACR, may be different between the types of DPP-4 inhibitors.Keywords: glomerular filtration rate, dipeptidyl peptidase 4, dipeptidyl peptidase 4 inhibitors, albuminuria
